Metformin is effective as first-line therapy in PCOS-induced anovulation, according to a recently published review and meta-analysis. The drug may also have the added benefit of improving the metabolic syndrome.
Researchers from Australia reviewed 13 trials that included a population of 543 women with polycystic ovary syndrome. They calculated that metformin is almost four times as effective at inducing ovulation as placebo, and that the combination of metformin and clomiphene is about 4.41 times as effective as clomiphene alone. In addition, metformin reduces fasting insulin concentrations, blood pressure, and low-density lipoprotein cholesterol. However, the drug may cause nausea, vomiting, and other gastrointestinal disturbances, and data regarding long-term safety and use in pregnancy are lacking.
Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951-953.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More